MEMENTO-VAScular COmponents of Dementia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

332 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-04

Study Completion Date

2021-10-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Multicenter national longitudinal cohort study including at least 800 individuals recruited from French Research Memory Centers and followed up over 36 months and included in Memento.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits

NCT04111211

Alzheimer Disease

COMPLETED

Longitudinal Study of Brain Amyloid imaGing in MEMENTO

NCT02164643

Alzheimer's Disease (AD) and Related Disorders

COMPLETED PHASE3

Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies

NCT04699786

Alzheimer Disease Dementia of Alzheimer Type

ACTIVE_NOT_RECRUITING NA

Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases

NCT02288000

Alzheimer Disease Battery

UNKNOWN PHASE1

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT06647498

Alzheimers Disease Dementia Alzheimers Disease, Familial

RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Alzheimer's disease (AD) is a neurodegenerative disorder thought to be caused by the accumulation of the peptide amyloid beta and the hyperphosphorylated tau protein in the brain. There are increasing arguments in favor of an important role of vascular damages in the development and progression of AD.

The time course of these vascular alterations and how they relate to dementia and AD pathology remain unclear, as no protocol that allows the development of the diverse vascular pathology to be scored, and hence to be tracked with ageing, has so far been developed and widely validated. The aims of this project are to investigate, in a large clinical sample of patients presenting either isolated cognitive complaints or light to mild cognitive deficits, how vascular risk factors and vascular alterations (assessed at macro and micro levels) relate to cerebrovascular disease and cognitive decline.

The primary objective of this ancillary study is to investigate the prospective association between vascular risk factors, inflammation markers and vascular damages on cognitive decline and neurodegeneration progression over up to 4 years of follow-up in a sample of individuals presenting with a spectrum of cognitive profiles ranging from isolated cognitive complaints to cognitive deficits without dementia.

The secondary objectives are the following

* To investigate the role of vascular risk factors (diabetes, hypertension, hypercholesterolemia) and vascular damages on progression to clinical dementia over up to 4-year follow-up.
* To study whether the interaction between changes in markers of macrovascular and microvascular structures on cognitive deficits progression.
* To study the association between in BP, hypertension, antihypertensive treatments and vascular damages, progression of cerebrovascular disease seen at MRI and cognitive decline and dementia risk
* To assess the temporality of vascular damages burden on neurodegeneration
* To assess the association between retinal vasculature defect and brain neurovascular damages
* To study the link between vascular damages and AD pathology (Cerebro-Spinal Fluid (CSF) and Positron emission tomography (TEP) amyloid imaging) biomarkers in the subsample of participants having all measures available
* To investigate how inflammatory markers mediate the association between vascular damages and neurodegeneration
* To assess whether vascular factors and neurodegenerative factors act independently or synergistically on the course of cognitive decline
* To assess simultaneously the impact of vascular damages on end organs (brain, eye, and kidney)
* To study the correlation between cerebral blood flow, measured by Arterial spin-Labeled (ASL) MRI and cognitive decline
* To study whether genetic polymorphisms revealed from genome-wide association studies (GWAS) of AD of vascular factors could modulate the association between vascular damages and cognitive decline

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease (AD) Alzheimer's Disease (AD) Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alzheimer's disease and related disorders

Group Type EXPERIMENTAL

in Memento-VASCOD

Intervention Type OTHER

* Pulse wave velocity assessment
* Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences
* Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement
* Neuropsychological testing and behaviorial and mood scales
* Urinary albumin excretion measurement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

in Memento-VASCOD

* Pulse wave velocity assessment
* Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences
* Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement
* Neuropsychological testing and behaviorial and mood scales
* Urinary albumin excretion measurement

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants to MEMENTO-Vascod should be included in MEMENTO.
* To have signed a specific MEMENTO-Vascod informed consent form, prior to any Vascod ancillary study related procedures
* To be aged 50 years old and above
* To have a Clinical Dementia Rating scale \<0.5 and to be not demented;